380 related articles for article (PubMed ID: 35189925)
1. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
3. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
[TBL] [Abstract][Full Text] [Related]
4. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
Shi L; Huang H; Lu X; Yan X; Jiang X; Xu R; Wang S; Zhang C; Yuan X; Xu Z; Huang L; Fu JL; Li Y; Zhang Y; Yao WQ; Liu T; Song J; Sun L; Yang F; Zhang X; Zhang B; Shi M; Meng F; Song Y; Yu Y; Wen J; Li Q; Mao Q; Maeurer M; Zumla A; Yao C; Xie WF; Wang FS
Signal Transduct Target Ther; 2021 Feb; 6(1):58. PubMed ID: 33568628
[TBL] [Abstract][Full Text] [Related]
5. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
Trials; 2022 May; 23(1):401. PubMed ID: 35562778
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.
Pochon C; Laroye C; Kimmoun A; Reppel L; Dhuyser A; Rousseau H; Gauthier M; Petitpain N; Chabot JF; Valentin S; de Carvalho Bittencourt M; Peres M; Aarnink A; Decot V; Bensoussan D; Gibot S
Front Med (Lausanne); 2023; 10():1224865. PubMed ID: 37706025
[TBL] [Abstract][Full Text] [Related]
7. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
[TBL] [Abstract][Full Text] [Related]
10. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
[TBL] [Abstract][Full Text] [Related]
11. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
13. Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.
Gorman EA; Rynne J; Gardiner HJ; Rostron AJ; Bannard-Smith J; Bentley AM; Brealey D; Campbell C; Curley G; Clarke M; Dushianthan A; Hopkins P; Jackson C; Kefela K; Krasnodembskaya A; Laffey JG; McDowell C; McFarland M; McFerran J; McGuigan P; Perkins GD; Silversides J; Smythe J; Thompson J; Tunnicliffe WS; Welters IDM; Amado-Rodríguez L; Albaiceta G; Williams B; Shankar-Hari M; McAuley DF; O'Kane CM
Am J Respir Crit Care Med; 2023 Aug; 208(3):256-269. PubMed ID: 37154608
[No Abstract] [Full Text] [Related]
14. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
16. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
Mazeraud A; Jamme M; Mancusi RL; Latroche C; Megarbane B; Siami S; Zarka J; Moneger G; Santoli F; Argaud L; Chillet P; Muller G; Bruel C; Asfar P; Beloncle F; Reignier J; Vinsonneau C; Schimpf C; Amour J; Goulenok C; Lemaitre C; Rohaut B; Mateu P; De Rudnicki S; Mourvillier B; Declercq PL; Schwebel C; Stoclin A; Garnier M; Madeux B; Gaudry S; Bailly K; Lamer C; Aegerter P; Rieu C; Sylla K; Lucas B; Sharshar T
Lancet Respir Med; 2022 Feb; 10(2):158-166. PubMed ID: 34774185
[TBL] [Abstract][Full Text] [Related]
18. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
[TBL] [Abstract][Full Text] [Related]
19. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.
Dilogo IH; Aditianingsih D; Sugiarto A; Burhan E; Damayanti T; Sitompul PA; Mariana N; Antarianto RD; Liem IK; Kispa T; Mujadid F; Novialdi N; Luviah E; Kurniawati T; Lubis AMT; Rahmatika D
Stem Cells Transl Med; 2021 Sep; 10(9):1279-1287. PubMed ID: 34102020
[TBL] [Abstract][Full Text] [Related]
20. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
Front Immunol; 2022; 13():932360. PubMed ID: 35860245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
